|
1
|
Hardy J and Selkoe DJ: The amyloid
hypothesis of Alzheimer's disease: Progress and problems on the
road to therapeutics. Science. 297:353–356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mucke L: Neuroscience: Alzheimer's
disease. Nature. 461:895–897. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Näslund J, Haroutunian V, Mohs R, Davis
KL, Davies P, Greengard P and Buxbaum JD: Correlation between
elevated levels of amyloid beta-peptide in the brain and cognitive
decline. JAMA. 283:1571–1577. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karran E, Mercken M and De Strooper B: The
amyloid cascade hypothesis for Alzheimer's disease: An appraisal
for the development of therapeutics. Nat Rev Drug Discov.
10:698–712. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun X, Sato S, Murayama O, Murayama M,
Park JM, Yamaguchi H and Takashima A: Lithium inhibits amyloid
secretion in COS7 cells transfected with amyloid precursor protein
C100. Neurosci Lett. 321:61–64. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li B, Ryder J, Su Y, Zhou Y, Liu F and Ni
B: FRAT1 peptide decreases Abeta production in swAPP(751) cells.
FEBS Lett. 553:347–350. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su Y, Ryder J, Li B, Wu X, Fox N,
Solenberg P, Brune K, Paul S, Zhou Y, Liu F and Ni B: Lithium, a
common drug for bipolar disorder treatment, regulates amyloid-beta
precursor protein processing. Biochemistry. 43:6899–6908. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ly PT, Wu Y, Zou H, Wang R, Zhou W,
Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J and Song W:
Inhibition of GSK3β-mediated BACE1 expression reduces
Alzheimer-associated phenotypes. J Clin Invest. 123:224–235. 2013.
View Article : Google Scholar
|
|
9
|
Brownlees J, Irving NG, Brion JP, Gibb BJ,
Wagner U, Woodgett J and Miller CC: Tau phosphorylation in
transgenic mice expressing glycogen synthase kinase-3beta
transgenes. Neuroreport. 8:3251–3255. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lucas JJ, Hernández F, Gómez-Ramos P,
Morán MA, Hen R and Avila J: Decreased nuclear beta-catenin, tau
hyperphosphorylation and neurodegeneration in GSK-3beta conditional
transgenic mice. EMBO J. 20:27–39. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engel T, Hernández F, Avila J and Lucas
JJ: Full reversal of Alzheimer's disease-like phenotype in a mouse
model with conditional overexpression of glycogen synthase
kinase-3. J Neurosci. 26:5083–5090. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ghanevati M and Miller CA:
Phospho-beta-catenin accumulation in Alzheimer's disease and in
aggresomes attributable to proteasome dysfunction. J Mol Neurosci.
25:79–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrari De GV, Papassotiropoulos A,
Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Sáez
K, Henríquez JP, Zhao A, et al: Common genetic variation within the
low-density lipoprotein receptor-related protein 6 and late-onset
Alzheimer's disease. Proc Natl Acad Sci USA. 104:9434–9439. 2007.
View Article : Google Scholar
|
|
14
|
Paccalin M, Pain-Barc S, Pluchon C, Paul
C, Besson MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R and Hugon J:
Activated mTOR and PKR kinases in lymphocytes correlate with memory
and cognitive decline in Alzheimer's disease. Dement Geriatr Cogn
Disord. 22:320–326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Z and Klionsky DJ: Mammalian
autophagy: Core molecular machinery and signaling regulation. Curr
Opin Cell Biol. 22:124–131. 2010. View Article : Google Scholar
|
|
16
|
Spilman P, Podlutskaya N, Hart MJ, Debnath
J, Gorostiza O, Bredesen D, Richardson A, Strong R and Galvan V:
Inhibition of mTOR by rapamycin abolishes cognitive deficits and
reduces amyloid-beta levels in a mouse model of Alzheimer's
disease. PLoS One. 5:e99792010. View Article : Google Scholar
|
|
17
|
Alonso A, Zaidi T, Novak M, Grundke-Iqbal
I and Iqbal K: Hyperphosphorylation induces self-assembly of tau
into tangles of paired helical filaments/straight filaments. Proc
Natl Acad Sci USA. 98:6923–6928. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mathew R, Karp CM, Beaudoin B, Vuong N,
Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al:
Autophagy suppresses tumorigenesis through elimination of p62.
Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vigneron F, Dos Santos P, Lemoine S,
Bonnet M, Tariosse L, Couffinhal T, Duplaà C and Jaspard-Vinassa B:
GSK-3β at the crossroads in the signalling of heart
preconditioning: Implication of mTOR and Wnt pathways. Cardiovasc
Res. 90:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
LaFerla FM, Green KN and Oddo S:
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev
Neurosci. 8:499–509. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iwata N, Tsubuki S, Takaki Y, Shirotani K,
Lu B, Gerard NP, Gerard C, Hama E, Lee HJ and Saido TC: Metabolic
regulation of brain Abeta by neprilysin. Science. 292:1550–1552.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farris W, Mansourian S, Chang Y, Lindsley
L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ and
Guenette S: Insulin-degrading enzyme regulates the levels of
insulin, amyloid beta-protein, and the beta-amyloid precursor
protein intracellular domain in vivo. Proc Natl Acad Sci USA.
100:4162–4167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang
J, Podlisny MB, Rosner MR, Safavi A, Hersh LB and Selkoe DJ:
Insulin-degrading enzyme regulates extracellular levels of amyloid
beta-protein by degradation. J Biol Chem. 273:32730–32738. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Son SM, Cha MY, Choi H, Kang S, Choi H,
Lee MS, Park SA and Mook-Jung I: Insulin-degrading enzyme secretion
from astrocytes is mediated by an autophagy-based unconventional
secretory pathway in Alzheimer disease. Autophagy. 12:784–800.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ballatore C, Lee VM and Trojanowski JQ:
Tau-mediated neuro-degeneration in Alzheimer's disease and related
disorders. Nat Rev Neurosci. 8:663–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan
M, Wisniewski HM and Binder LI: Abnormal phosphorylation of the
microtubule-associated protein tau (tau) in Alzheimer cytoskeletal
pathology. Proc Natl Acad Sci USA. 83:4913–4917. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rubinsztein DC: The roles of intracellular
protein-degradation pathways in neurodegeneration. Nature.
443:780–786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chesser AS, Pritchard SM and Johnson GV:
Tau clearance mechanisms and their possible role in the
pathogenesis of Alzheimer disease. Front Neurol. 4:1222013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hara T, Nakamura K, Matsui M, Yamamoto A,
Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I,
Okano H and Mizushima N: Suppression of basal autophagy in neural
cells causes neurodegenerative disease in mice. Nature.
441:885–889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Martinez-Vicente M, Krüger U,
Kaushik S, Wong E, Mandelkow EM, Cuervo AM and Mandelkow E: Tau
fragmentation, aggregation and clearance: The dual role of
lysosomal processing. Hum Mol Genet. 18:4153–4170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Long ZM, Zhao L, Jiang R, Wang KJ, Luo SF,
Zheng M, Li XF and He GQ: Valproic acid modifies synaptic structure
and accelerates neurite outgrowth via the glycogen synthase
kinase-3β signaling pathway in an Alzheimer's disease model. CNS
Neurosci Ther. 21:887–897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kempf SJ, Metaxas A, Ibáñez-Vea M, Darvesh
S, Finsen B and Larsen MR: An integrated proteomics approach shows
synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model.
Oncotarget. 7:33627–33648. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong L, Liu H, Zhang W, Liu X, Jiang B,
Fei H and Sun Z: Ellagic acid ameliorates learning and memory
impairment in APP/PS1 transgenic mice via inhibition of β-amyloid
production and tau hyperphosphorylation. Exp Ther Med.
16:4951–4958. 2018.PubMed/NCBI
|
|
34
|
Mariño G, Madeo F and Kroemer G: Autophagy
for tissue homeostasis and neuroprotection. Curr Opin Cell Biol.
23:198–206. 2011. View Article : Google Scholar
|
|
35
|
Pivtoraiko VN, Harrington AJ, Mader BJ,
Luker AM, Caldwell GA, Caldwell KA, Roth KA and Shacka JJ: Low-dose
bafilomycin attenuates neuronal cell death associated with
autophagy-lysosome pathway dysfunction. J Neurochem. 114:1193–1204.
2010.PubMed/NCBI
|
|
36
|
Chu CT: Autophagy in different flavors:
Dysregulated protein degradation in neurological diseases.
Neurobiol Dis. 43:1–3. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Galluzzi L, Maiuri MC, Vitale I, Zischka
H, Castedo M, Zitvogel L and Kroemer G: Cell death modalities:
Classification and pathophysiological implications. Cell Death
Differ. 14:1237–1243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mullen RJ, Buck CR and Smith AM: NeuN, a
neuronal specific nuclear protein in vertebrates. Development.
116:201–211. 1992.PubMed/NCBI
|
|
39
|
Komatsu M, Waguri S, Chiba T, Murata S,
Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E and
Tanaka K: Loss of autophagy in the central nervous system causes
neurodegeneration in mice. Nature. 441:880–884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Omata Y, Lim YM, Akao Y and Tsuda L:
Age-induced reduction of autophagy-related gene expression is
associated with onset of Alzheimer's disease. Am J Neurodegener
Dis. 3:134–142. 2014.
|
|
41
|
Salminen A, Kaarniranta K, Kauppinen A,
Ojala J, Haapasalo A, Soininen H and Hiltunen M: Impaired autophagy
and APP processing in Alzheimer's disease: The potential role of
Beclin 1 interactome. Prog Neurobiol. 106-107:33–54. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jaeger PA, Pickford F, Sun CH, Lucin KM,
Masliah E and Wyss-Coray T: Regulation of amyloid precursor protein
processing by the Beclin 1 complex. PLoS One. 5:e111022010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pickford F, Masliah E, Britschgi M, Lucin
K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E,
Levine B and Wyss-Coray T: The autophagy-related protein beclin 1
shows reduced expression in early Alzheimer disease and regulates
amyloid beta accumulation in mice. J Clin Invest. 118:2190–2199.
2008.PubMed/NCBI
|
|
44
|
Sarkar S, Perlstein EO, Imarisio S, Pineau
S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ,
Schreiber SL and Rubinsztein DC: Small molecules enhance autophagy
and reduce toxicity in Huntington's disease models. Nat Chem Biol.
3:331–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Williams A, Sarkar S, Cuddon P, Ttofi EK,
Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, et
al: Novel targets for Huntington's disease in an mTOR-independent
autophagy pathway. Nat Chem Biol. 4:295–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Balgi AD, Fonseca BD, Donohue E, Tsang TC,
Lajoie P, Proud CG, Nabi IR and Roberge M: Screen for chemical
modulators of autophagy reveals novel therapeutic inhibitors of
mTORC1 signaling. PLoS One. 4:e71242009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jimenez-Sanchez M, Thomson F, Zavodszky E
and Rubinsztein DC: Autophagy and polyglutamine diseases. Prog
Neurobiol. 97:67–82. 2012. View Article : Google Scholar
|
|
48
|
Bové J, Martinez-Vicente M and Vila M:
Fighting neurodegeneration with rapamycin: Mechanistic insights.
Nat Rev Neurosci. 12:437–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Embi N, Rylatt DB and Cohen P: Glycogen
synthase kinase-3 from rabbit skeletal muscle. Separation from
cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J
Biochem. 107:519–527. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Doble BW and Woodgett JR: Role of glycogen
synthase kinase-3 in cell fate and epithelial-mesenchymal
transitions. Cells Tissues Organs. 185:73–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Forde JE and Dale TC: Glycogen synthase
kinase 3: A key regulator of cellular fate. Cell Mol Life Sci.
64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Llorens-Martin M, Jurado J, Hernández F
and Avila J: GSK-3β, a pivotal kinase in Alzheimer disease. Front
Mol Neurosci. 7:462014.
|
|
53
|
Rockenstein E, Torrance M, Adame A, Mante
M, Bar-on P, Rose JB, Crews L and Masliah E: Neuroprotective
effects of regulators of the glycogen synthase kinase-3beta
signaling pathway in a transgenic model of Alzheimer's disease are
associated with reduced amyloid precursor protein phosphorylation.
J Neurosci. 27:1981–1991. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Koh SH, Noh MY and Kim SH:
Amyloid-beta-induced neuro-toxicity is reduced by inhibition of
glycogen synthase kinase-3. Brain Res. 1188:254–262. 2008.
View Article : Google Scholar
|
|
55
|
Terwel D, Muyllaert D, Dewachter I,
Borghgraef P, Croes S, Devijver H and Van Leuven F: Amyloid
activates GSK-3beta to aggravate neuronal tauopathy in bigenic
mice. Am J Pathol. 172:786–798. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lin SY, Li TY, Liu Q, Zhang C, Li X, Chen
Y, Zhang SM, Lian G, Liu Q, Ruan K, et al: GSK3-TIP60-ULK1
signaling pathway links growth factor deprivation to autophagy.
Science. 336:477–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cohen P and Frame S: The renaissance of
GSK3. Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Woodgett JR and Ohashi PS: GSK3: An
in-Toll-erant protein kinase? Nat Immunol. 6:751–752. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang HH, Lipovsky AI, Dibble CC, Sahin M
and Manning BD: S6K1 regulates GSK3 under conditions of
mTOR-dependent feedback inhibition of Akt. Mol Cell. 24:185–197.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Salinas PC and Zou Y: Wnt signaling in
neural circuit assembly. Annu Rev Neurosci. 31:339–358. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Inestrosa NC and Arenas E: Emerging roles
of Wnts in the adult nervous system. Nat Rev Neurosci. 11:77–86.
2010. View Article : Google Scholar
|
|
62
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ciani L and Salinas PC: WNTs in the
vertebrate nervous system: From patterning to neuronal
connectivity. Nat Rev Neurosci. 6:351–362. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gordon MD and Nusse R: Wnt signaling:
Multiple pathways, multiple receptors, and multiple transcription
factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Inestrosa NC, Montecinos-Oliva C and
Fuenzalida M: Wnt signaling: Role in Alzheimer disease and
schizophrenia. J Neuroimmune Pharmacol. 7:788–807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lin AL, Jahrling JB, Zhang W, DeRosa N,
Bakshi V, Romero P, Galvan V and Richardson A: Rapamycin rescues
vascular, metabolic and learning deficits in apolipoprotein E4
transgenic mice with pre-symptomatic Alzheimer's disease. J Cereb
Blood Flow Metab. 37:217–226. 2017. View Article : Google Scholar
|
|
68
|
Liu W, Guo J, Mu J, Tian L and Zhou D:
Rapamycin protects sepsis-induced cognitive impairment in mouse
hippocampus by enhancing autophagy. Cell Mol Neurobiol.
37:1195–1205. 2017. View Article : Google Scholar
|
|
69
|
Sarbassov DD, Ali SM and Sabatini DM:
Growing roles for the mTOR pathway. Curr Opin Cell Biol.
17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
|
